8/1/2013 8:05:30 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
July 31, 2013 -- Takeda Pharma, Japan’s largest drugmaker, has been granted CFDA approval for Nesina (alogliptin), a treatment for type 2 diabetes. Nesina is a dipeptidyl peptidase-4 inhibitor (DPP-4). The DPP-4 drugs increase a person’s insulin response and offer both a low-side-effect profile and the convenience of oral administration. More details....
Stock Symbol: (TO: 4502)
Help employers find you! Check out all the jobs and post your resume.
comments powered by